ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
ZUG, Switzerland, April 05, 2016 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that Thomas Meyer, Ph.D., Chairman and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 2:20 p.m. EDT from The Westin New York Grand Central hotel in New York City. The webcast will be available through the Events and Presentations page in the Investors section of the Company's website (www.aurismedical.com).
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Company contact: Cindy McGee, Head of Investor Relations and Corporate Communications +41 61 201 1350, [email protected] Agency contact: Matthew P. Duffy, Managing Director, LifeSci Advisors 212-915-0685, [email protected]
